As part of the surveillance protocol for CDI, between November 2013 and December 2015, all hospitalized patients with a hospital stay more significant than 48 h who developed diarrhea (3 or more depositions in the last 24 h with a Bristol score of 6 or 7 or a recent hospitalization in the previous 12 weeks) were tested for C. difficile using the Cepheid Xpert C. difficile/Epi test (Cepheid, Sunnyvale CA).
Xpert c difficile epi test
Manufactured by Cepheid
The Xpert C. difficile/Epi test is a molecular diagnostic assay designed to detect the presence of Clostridioides difficile (C. diff) and its epigenetic variants in stool samples. The test utilizes real-time PCR technology to provide rapid and accurate results, enabling healthcare professionals to make informed decisions about patient management.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using xpert c difficile epi test
1
Surveillance Protocol for C. difficile Infection
2
Diagnosis and Classification of Recurrent Clostridium difficile Infection
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients with unexplained diarrhea (≥ 3 unformed stools, Bristol scale 5–7) within 24 h were included. For the diagnosis of CDI, fecal samples were collected, and C. difficile was investigated by real-time PCR (Cepheid Xpert C. difficile/Epi test, Cepheid, Sunnyvale CA). Patients were defined with CDI when patients were diarrheal and PCR was positive.
R-CDI was defined by the reappearance of diarrhea associated with CDI within eight weeks after the completion of antibiotic therapy or the resolution of the initial episode [21 (link)]. CDI was classified as NR-CDI when no new episode occurred within eight weeks. Data collected from patients with R-CDI and NR-CDI included epidemiological and clinical data, prior antibiotic therapy, and treatment for CDI. The study was reviewed and approved by the Local Ethics Committee (Approval: 047/16).
R-CDI was defined by the reappearance of diarrhea associated with CDI within eight weeks after the completion of antibiotic therapy or the resolution of the initial episode [21 (link)]. CDI was classified as NR-CDI when no new episode occurred within eight weeks. Data collected from patients with R-CDI and NR-CDI included epidemiological and clinical data, prior antibiotic therapy, and treatment for CDI. The study was reviewed and approved by the Local Ethics Committee (Approval: 047/16).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!